-
Delcath Systems (DCTH) PT Lowered to $19 at BTIG
-
Delcath Systems (DCTH) Tops Q4 EPS by 3c
-
Delcath Systems reports preliminary 2025 revenue of $85.2 million
-
Delcath announces study showing 29-month survival for liver cancer treatment
-
Delcath Systems reports study showing liver therapy benefits for melanoma
-
Delcath Systems (DCTH) Tops Q3 EPS by 5c ; Offers Guidance
-
Delcath Systems (DCTH) PT Lowered to $30 at H.C. Wainwright
-
Delcath Systems reports Q3 revenue of $20.5 million, raises 2025 guidance
-
Delcath Systems reports CHOPIN trial meets primary endpoint
-
Delcath Systems (DCTH) Tops Q2 EPS by 4c ; Offers Guidance
-
Delcath Systems (DCTH) PT Raised to $29 at H.C. Wainwright
-
BTIG Reiterates Buy Rating on Delcath Systems (DCTH)
-
Delcath Systems (DCTH) Issues Full Year 2025 Guidance
-
Delcath Systems (DCTH) PT Raised to $26 at Clear Street
-
Delcath Systems (DCTH) Tops Q1 EPS by 1c
-
Delcath Systems (DCTH) Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
-
Beta Bionics (BBNX) appoints Gerard Michel to Board
-
Delcath Systems (DCTH) reports inducement grants
-
Delcath Systems (DCTH) PT Raised to $24 at H.C. Wainwright
-
Delcath Systems (DCTH) PT Raised to $22 at BTIG
-
Delcath Systems (DCTH) Misses Q4 EPS by 11c
-
Delcath Systems (DCTH) PT Raised to $21 at Craig-Hallum
-
Delcath Systems (DCTH) Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
-
Delcath Systems (DCTH) Announces Additional $16.3M in Funding From Series E and E1 Warrant Exercises
-
Clear Street Starts Delcath Systems (DCTH) at Buy
-
Delcath Systems (DCTH) Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
-
Delcath Systems (DCTH) Tops Q3 EPS by 26c
-
H.C. Wainwright Reiterates Buy Rating on Delcath Systems (DCTH)
-
Delcath Systems (DCTH) Reports Prelim Q3 Results
-
Delcath Systems (DCTH) Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients
-
Delcath Systems (DCTH) Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors
-
Delcath Systems (DCTH) PT Raised to $20 at BTIG
-
Delcath Systems (DCTH) Misses Q2 EPS by 12c
-
Delcath Systems (DCTH) Files $100M Mixed Shelf

